STVN

Stevanato Group S.p.A.

Next est. report 2026-11-05 · BMO

GLP-1 Long '24: GLP1 Equip/Distrib GLP-1 Long '24: Peptide Producers/Designers MedTech Long '26: Life Science Tools & Bioprocessing

Loading…

Loading chart…

Overview

Stevanato Group S.p.A. provides integrated solutions for pharmaceutical and healthcare sectors. Its Biopharmaceutical and Diagnostic Solutions (BDS) segment, th

Stevanato Group S.p.A. provides integrated solutions for pharmaceutical and healthcare sectors. Its Biopharmaceutical and Diagnostic Solutions (BDS) segment, the primary revenue driver, offers drug containment (syringes, vials) and delivery systems (like Alina and Deora pens) for biologics and GLP-1s. The Engineering segment supplies specialized machinery. They serve global pharmaceutical and biotech companies, focusing on high-value, integrated offerings.

Search Keywords Brand Product

Nexa syringes
Alba syringes
EZ-fill vials
Alina pen
Deora pen
ready-to-fill cartridges
drug delivery systems
visual inspection machines
assembly lines
glass converting
biologics manufacturing
GLP-1 therapies
injectable therapies
biosimilars
self-administration of medicines
pharmaceutical packaging
integrated solutions
fill-finish capacity
supply chain reliability
high-value solutions

Search Keywords Event Phrases

Stevanato Group Q2 2026 earnings
Alina European approval
Fishers facility commercial production
Latina RTU cartridge line

Search Keywords Policy Regulatory

EU GMP Annex 1 regulations
pharma reshoring incentives

What They Do (Plain English & Analogies): Stevanato Group is like a specialized toolkit provider for pharmaceutical companies. Imagine drug manufacturers need to put their medicines into very specific, high-quality containers (like tiny glass vials, syringes, or cartridges) and sometimes also need the devices to inject them (like auto-injectors or pen injectors). Stevanato Group makes these containers and injection devices. They also build the highly precise machines that pharmaceutical companies use to make, inspect, assemble, and package these containers and devices themselves. So, they offer both the 'packaging' and 'delivery tools' for drugs, especially complex injectable medicines like biologics, and the 'factory equipment' to produce them. They are mission-critical to the delivery of biologics, supporting new therapeutic areas, expanding global access to treatments, and improving standards of care.
Very Brief History: Founded in 1949 by Giovanni Stevanato as Soffieria Stella, a handmade glass laboratory in Zelarino, Italy, the company initially produced glass bottles. In 1959, it moved to Piombino Dese and later established Ompi in 1969, specializing in pharmaceutical glass packaging. A key milestone was the founding of SPAMI in 1971, which focused on designing and building high-speed precision machinery for glass tube containers, creating an integrated model. The company expanded internationally through acquisitions and greenfield projects, launching its pre-sterilized EZ-fill® syringes in 2007 and going public on the NYSE in 2021 under the ticker STVN.
"Street Stereotype": Stevanato Group is generally perceived by investors and analysts as a 'picks and shovels' play on the growth of injectable drugs, particularly biologics and self-administered medicines. The market views it as a high-quality, family-influenced business with a strong competitive position in high-precision pharmaceutical packaging. There's a focus on its integrated model (providing both containment/delivery solutions and the machinery to produce them) as a key competitive advantage. However, there are also concerns regarding the slower-than-anticipated turnaround of its Engineering segment and potential impacts from the rise of oral GLP-1 therapies on its injectable-focused business. Analyst consensus is a 'Moderate Buy'.
Subsidiaries On Linked In*: Ompi — Division/brand of Stevanato Group
Balda — Division/brand of Stevanato Group (plastics solutions), includes German facility for Alina production
Spami — Division/brand of Stevanato Group (Engineering Systems)
Optrel — Division/brand of Stevanato Group (Engineering Systems)
InnoScan — Division/brand of Stevanato Group (Engineering Systems)
SVM — Division/brand of Stevanato Group (Engineering Systems)
Customer Sectors & Example Clients: Stevanato Group's customers are primarily in the pharmaceutical, biotechnology, and life sciences industries. They serve companies developing and manufacturing small molecules, highly sensitive drugs, vaccines, RNA-based drugs, GLP-1 and peptides, and monoclonal antibodies (mAbs) and Antibody-Drug Conjugates (ADCs). They work with 'big international clients,' 'bio customer,' 'originators,' and 'biosimilar clients.' While specific client names are not explicitly stated in the recent transcript, based on their market position and product focus, likely clients include major global pharmaceutical companies and Contract Development and Manufacturing Organizations (CDMOs) such as Eli Lilly and Novo Nordisk (for GLP-1s), and other top-tier biotech firms.
New Customers / Segments They'Re Targeting: Stevanato Group is strategically targeting the rapidly growing market for injectable biologics, including biosimilars, monoclonal antibodies, and GLP-1 therapies. They are particularly focused on customers seeking integrated solutions that combine device innovation, manufacturing expertise, and supply chain reliability for drug delivery systems. The company aims to maximize its penetration in the broader biologics space, which includes hundreds of clients from large organizations to small start-ups, and various therapeutic areas beyond GLP-1s. They are also expanding their offerings for treatments requiring strict patient adherence to dosing regimens, as evidenced by their new Deora pen system.
Supply Chain And Sourcing Geographies: Stevanato Group's supply chain includes manufacturing facilities in Europe, North America, and Asia. Key production sites are located in Piombino Dese and Latina in Italy, Bratislava in Slovakia, Monterrey in Mexico, and Zhangjiagang in China. They are also building a new plant in Sete Lagoas, Brazil. Significant investments are being made to expand capacity for high-value solutions in Fishers, Indiana (United States) and Latina, Italy, to meet rising global demand. The Fishers facility is intended to mirror the capabilities in Europe, particularly for EZ-fill technology, and to serve as a domestic supply chain for U.S. clients. Their proprietary devices, such as the Alina pen platform, are manufactured in their facility in Germany. The company has also consolidated offices in Denmark and moved visual inspection activities to Italy, acquiring a new location in Bologna, Italy, to access strong technical talent.
Sales Geographies And Expansion Plans: Stevanato Group sells its products globally. The company has a global footprint which provides supply chain security to its customers. Specific regions mentioned for growth and customer engagement include the United States, Europe, and Asia for biosimilars. The recent regulatory approval for their Alina pen platform for a liraglutide-based therapy was in several European countries, with additional validation expected in North America in the second half of the year. Engineering segment orders are being won in Europe and Asia, and technology for assembly for drug delivery systems in Europe and the United States. The investments in Fishers, Indiana, are aimed at serving the domestic United States market, while Latina, Italy, serves regional and national customers. The company is focused on expanding its presence in the broader global market for injectable biologics and biosimilars.
How Key Themes May Help/Hurt: Stevanato Group is strongly positioned to benefit from the 'MedTech Long '26: Life Science Tools & Bioprocessing' theme. The surging demand for complex biologics and GLP-1 therapeutics directly drives demand for their specialized bioprocessing consumables, advanced fill-finish capacity, and high-value drug delivery systems, including self-administration platforms. The sustained recovery in biotech venture capital funding fuels early-stage R&D, which in turn increases the drug pipeline and demand for Stevanato's containment and delivery solutions. Accelerated pharma reshoring, particularly in the U.S. (e.g., Fishers facility), and increased CDMO outsourcing, driven by supply chain resilience and government incentives, also directly benefit Stevanato's capacity expansions. The continuous industry adaptation to EU GMP Annex 1 regulations drives sustained investment in advanced cleanroom technologies and aseptic processing solutions, which aligns with Stevanato's focus on high-quality, ready-to-use platforms. While the theme is generally bullish, slower decision-making in capital equipment orders and persistent budgetary constraints in some sectors could slightly temper the pace of growth for their Engineering segment.

3 Main Long-Term Bull Details

Leadership in High-Value Solutions for Biologics and GLP-1s: Stevanato Group is strategically focused on high-value solutions (HVS), which represented 45% of Q2 2026 revenue and are expected to reach 47-48% for FY26. This is driven by robust and growing demand for injectable biologics (42% of BDS revenue) and GLP-1 therapies (22-23% of total revenue), where the company holds a leadership position with products like Nexa and Alba syringes, EZ-fill vials and cartridges, and proprietary pen platforms like Alina and Deora.
Integrated End-to-End Solutions and Proprietary Devices: The company's unique integrated model, offering both drug containment (e.g., cartridges) and proprietary drug delivery systems (e.g., Alina pen platform), combined with manufacturing expertise and supply chain reliability, positions it as a strategic partner for pharmaceutical customers seeking comprehensive solutions. This integrated approach, validated by recent regulatory approvals for Alina in Europe, enhances customer stickiness and differentiates Stevanato in the market.
Strategic Capacity Expansions and Global Footprint: Significant capital investments in new and expanding facilities in Fishers, Indiana (U.S.), and Latina, Italy, are ramping up to meet surging global demand for high-value solutions. These expansions, including new RTU cartridge lines and device manufacturing capabilities, strengthen their operational maturity, provide domestic supply chain security for key markets, and are expected to drive future revenue growth and margin expansion.

3 Main Long-Term Bear Details

Underperformance and Elongated Sales Cycles in Engineering Segment: The Engineering segment continues to be a drag on overall performance, with revenue declining 2% in Q2 2026. Despite optimization efforts, slower order intake, longer sales cycles due to more disciplined customer procurement, and a low backlog are delaying its return to historical performance, impacting overall company growth and profitability.
Currency Headwinds and Higher Depreciation Costs: Foreign currency translation is expected to remain a headwind, impacting revenue for fiscal 2026. Additionally, higher depreciation expenses related to the ramp-up of new facilities in Fishers and Latina, along with increased utility costs, continue to exert pressure on gross profit margins, partially offsetting gains from a better product mix.
Normalization of GLP-1 Growth and Market Evolution: While GLP-1s remain a significant tailwind, their growth is normalizing to an expected mid-teens in 2026, following higher growth rates in prior periods. Although management views oral GLP-1s as market expansion rather than cannibalization, the evolving market dynamics and potential shifts in drug delivery preferences introduce uncertainties and could impact the long-term growth trajectory of injectable-focused solutions.

Competitors And Differentiation: Stevanato Group operates in a competitive landscape within pharmaceutical packaging, drug delivery systems, and specialized machinery. A key competitor in injectable packaging components and syringe components is West Pharmaceutical Services (WST). Stevanato differentiates itself through its 'integrated system approach' and 'end-to-end capabilities,' offering a broad portfolio that combines device innovation, manufacturing expertise, and supply chain reliability. Unlike some competitors, they don't just sell drug delivery systems but integrate their own glass cartridges within their proprietary devices like the Alina pen platform. This 'one-stop-shop' approach, providing both containment/delivery solutions and the machinery to produce them, creates strong customer stickiness and aims to position them as a leader in biologic applications, particularly for higher-value subsets of the market.
Recent Performance & What The Market'S Focused On: Stevanato Group reported solid second-quarter 2026 financial results, largely in line with expectations. Revenue grew 8% year-over-year to EUR 302 million, driven by a 9% increase in the Biopharmaceutical and Diagnostic Solutions (BDS) segment, which offset a slight 2% decline in the Engineering segment. Revenue from high-value solutions grew 16% and represented 45% of total company revenue, with biologics revenue increasing 30%. The company completed the divestiture of its California-based subsidiary, Balda C. Brewer, as part of its strategy to optimize its footprint towards more complex drug delivery systems. Adjusted EBITDA increased 21% to EUR 78.7 million, with an adjusted EBITDA margin of 26%. The market is focused on the continued strength of the BDS segment, particularly the growth of high-value solutions and GLP-1 therapies (22-23% of total revenue), the successful ramp-up of new capacities in Fishers and Latina, and the progress in improving the Engineering segment's performance. The recent regulatory approval of their proprietary Alina variable dose pen platform in Europe is also a key commercial milestone being watched, signaling future growth in drug delivery systems. The company updated its full-year 2026 guidance, narrowing the revenue range to EUR 1.260 billion to EUR 1.280 billion, with adjusted EBITDA between EUR 335 million and EUR 345.2 million.

Revenue Segments And Estimated Mix: Biopharmaceutical and Diagnostic Solutions (BDS) — Mix: ~88.1%; Source: Q2 2026 transcript; Trend: 9% reported growth in Q2 2026
Engineering — Mix: ~11.9%; Source: Q2 2026 transcript; Trend: -2% reported decline in Q2 2026
High-Value Solutions (within total revenue) — Mix: 45%; Source: Q2 2026 transcript; Trend: 16% growth in Q2 2026; expected 47-48% for FY26
GLP-1s (product category within total revenue) — Mix: 22-23%; Source: Q2 2026 transcript; Trend: Strong long-term durable tailwinds expected
Biologics (within BDS segment revenue) — Mix: ~42%; Source: Q2 2026 transcript; Trend: 6% growth in Q2 2026
Other Containment and Delivery Solutions (within BDS) — Mix: n/m; Source: Q2 2026 transcript; Trend: 3% growth in Q2 2026
Product Brands: Nexa
Alba
EZ-fill
Alina
Deora
Vertiva
Fina
MAVIS
Ompi
Balda
Spami
Optrel
InnoScan
SVM

Bull / Bear Details

Stevanato Group remains a compelling investment as of 2026-08-12, driven by robust demand for high-value solutions in its Biopharmaceutical and Diagnostic Solut

Thesis

Stevanato Group remains a compelling investment as of 2026-08-12, driven by robust demand for high-value solutions in its Biopharmaceutical and Diagnostic Solutions (BDS) segment, particularly for biologics and GLP-1s. Strategic capacity expansions are ramping up, and the recent regulatory approval of the Alina pen platform reinforces its move towards integrated, differentiated drug delivery systems. While the Engineering segment continues to face challenges and longer sales cycles, strong execution in premium products and market tailwinds position STVN for sustained long-term growth and margin expansion.

Bull case

Stevanato Group continues to demonstrate strong growth in high-value solutions (HVS), which grew 16% year-over-year in Q2 2026 and represented 45% of total revenue. This is fueled by ongoing demand for biologics (42% of BDS revenue, 30% growth in Q2 2026 for biologics revenue within HVS) and GLP-1s (22-23% of total revenue), diversifying growth drivers and positioning the company in high-growth therapeutic areas.
The company's significant capital investments in its Fishers (US) and Latina (Italy) facilities are effectively ramping up. The first EZ-fill vial line at Fishers is nearing customer validation, and commercial production for its first device program is expected later this year. The Latina syringe ramp-up is ongoing, with a new RTU 400 cartridge line expected in 2027, supporting future capacity and growth.
Stevanato Group is strategically moving up the value chain with its integrated drug delivery systems. The regulatory approval of its proprietary Alina variable dose pen platform for liraglutide-based therapies in Europe, with North American approvals anticipated, is a significant commercial milestone. This, along with the introduction of Deora, reinforces the company's leadership in integrated solutions that combine devices and cartridges.

Bear case

The Engineering segment continues to underperform, with revenue declining 2% in Q2 2026. Despite ongoing optimization efforts leading to improved margins, slower order intake and longer sales cycles persist, delaying its return to historical performance and acting as a drag on overall company growth and profitability.
Foreign currency translation remains a headwind, and higher depreciation related to the ramp-up of new facilities in Fishers and Latina continues to exert pressure on gross profit margins. Additionally, the effective tax rate in Q2 2026 was higher due to the absence of a prior-year tax incentive and no corresponding tax benefit on the Balda C. Brewer divestiture.
While GLP-1s remain a significant tailwind, management expects double-digit growth for 2026, a normalization from prior higher growth rates. The broader industry faces lengthening sales cycles, indicating slower decision-making for customers, which could impact order intake and project phasing across segments.

Bull / Bear Case

Bear Case: The bear case for Stevanato Group is primarily anchored by the persistent underperformance of its Engineering segment, which saw a 2% revenue decline in Q2 2026. Despite optimization efforts, elongated sales cycles and slower order intake continue to delay its recovery, acting as a drag on overall profitability. Furthermore, the company faces headwinds from foreign currency translation and higher depreciation expenses associated with the ramp-up of new facilities, which pressure gross profit margins. While GLP-1s remain a growth driver, management anticipates a normalization to double-digit growth in 2026 from previously higher rates, introducing uncertainty. The broader industry's lengthening sales cycles could also impact order intake and project phasing across segments, posing execution challenges.
Bull Case: Stevanato Group presents a compelling bull case driven by its strategic focus on high-value solutions (HVS), which grew 16% year-over-year in Q2 2026 and are projected to reach 47-48% of total revenue for FY26. This growth is fueled by robust demand for injectable biologics, representing 42% of BDS revenue, and GLP-1 therapies, accounting for 22-23% of total revenue, both offering significant long-term tailwinds. The recent regulatory approval of the proprietary Alina variable dose pen platform in Europe, with North American approvals anticipated, marks a crucial commercial milestone, reinforcing the company's leadership in integrated drug delivery systems. Ongoing capital investments in Fishers (US) and Latina (Italy) are successfully ramping up, expanding capacity for key products like EZ-fill vials and syringes, and are expected to drive future revenue growth and margin expansion.
More Compelling & Why: Bull. Despite some headwinds, the company's forward P/E ratio of approximately 28x is notably lower than its peer West Pharmaceutical Services (~38x), suggesting a relative discount. The strongest argument for the bull case is Stevanato's strategic pivot towards high-value, integrated solutions for the rapidly expanding biologics and GLP-1 markets, evidenced by the successful Alina pen approval and ongoing capacity expansions. This focus positions them for sustainable long-term growth. My view would flip if the company fails to achieve positive free cash flow for fiscal year 2026 or if the ramp-up of new facilities experiences significant, prolonged delays, impacting future profitability and cash generation.

Key Factors5 rows

Key Factor	Why It Matters	What To Watch	What It Signals	Where/How To Track	Free Alt Data	Paid Alt Data
Alina Pen Platform Regulatory Approvals and Commercial Traction	This represents a significant commercial milestone for Stevanato's proprietary drug delivery systems, validating years of R&D and opening new revenue streams in high-value biologics and GLP-1 markets.	Confirmation of additional regulatory approvals for Alina in North America in H2 2026; management commentary on the pace of customer adoption and initial revenue contribution from Alina products in Q3/Q4 2026.	Bullish: Confirmation of North American regulatory approval for Alina in H2 2026, or management reporting double-digit revenue growth from Alina products in subsequent quarters. Bearish: Delays in North American approvals or slower-than-expected customer adoption and revenue generation.	Company earnings calls and press releases (Q3 2026 earnings call estimated for November 10, 2026).	Google Trends: 'Alina pen Stevanato', 'liraglutide pen approval'. Industry news sites (e.g., Fierce Pharma, BioProcess International) for announcements on drug delivery device approvals.	EvaluatePharma: New drug approvals incorporating Stevanato devices. IQVIA: Prescription data for liraglutide-based therapies using Alina pen.
Engineering Segment Order Intake and Backlog Growth	The Engineering segment has been a drag on overall performance. Improved order intake and backlog are crucial for its recovery, contributing to overall company growth and profitability.	Management commentary on new order intake and backlog conversion rates in Q3 2026. Watch for the year-over-year revenue decline in the Engineering segment to moderate faster than the mid-single to low double-digit guidance for FY26.	Bullish: Management reports a significant increase in new order intake, a faster-than-expected rebuild of the backlog, or a moderation of revenue decline beyond the guided range. Bearish: Continued slow order intake, further delays in converting pipeline to orders, or revenue decline at the higher end of the guidance range.	Company earnings calls and press releases (Q3 2026 earnings call estimated for November 10, 2026).	Industry reports on pharmaceutical capital expenditure trends. PwC's 'Pharmaceutical and life sciences: US Deals midyear outlook' for insights on deal activity and capital allocation.	Thinknum: Engineering job postings (e.g., 'Stevanato Engineering' job growth).
High-Value Solutions (HVS) Revenue Contribution and Growth	HVS is the primary driver of Stevanato Group's revenue growth and margin expansion, reflecting its strategic shift towards premium offerings in biologics and self-administration.	HVS revenue as a percentage of total revenue (2026 guidance: 47-48%) and its year-over-year growth rate in subsequent quarters. Q2 2026 HVS revenue was 45% of total, growing 16% Y/Y.	Bullish: HVS revenue consistently at or above 47% of total revenue and Y/Y growth exceeding 16% (Q2 2026 rate). Bearish: HVS revenue falling below 45% of total revenue or significant deceleration in Y/Y growth below 16%.	Company earnings calls and press releases (Q3 2026 earnings call estimated for November 10, 2026).	Industry reports on biologics market growth and drug delivery systems adoption.	FactSet/Bloomberg: Consensus estimates for STVN HVS revenue.
Commercial Production Launch at Fishers, Indiana Facility	The Fishers facility is a critical growth investment for expanding high-value solutions capacity in the US, crucial for meeting customer demand and reinforcing domestic supply chains for biologics.	Official announcement of commercial production beginning at the Fishers facility for the first EZ-fill vial line and the first device program, with specific timelines for Q3/Q4 2026.	Bullish: Commercial production begins as expected later in 2026, or earlier, with initial volumes exceeding expectations. Bearish: Delays in the start of commercial production beyond Q4 2026.	Company earnings calls and press releases (Q3 2026 earnings call estimated for November 10, 2026).	Local news reports in Fishers, Indiana, for facility updates. Industry publications (e.g., BioProcess International) for new facility ramp-up news.	Satellite imagery: Construction progress at Fishers facility. Thinknum: Job postings for production roles at Fishers facility.
GLP-1 Related Revenue Growth Rate	GLP-1s are a significant and growing therapeutic area, representing approximately 22% to 23% of Stevanato's total revenue. Sustained double-digit growth is crucial for capitalizing on this market tailwind.	The year-over-year growth rate of GLP-1 revenue in subsequent quarterly reports. Management expects double-digit growth for GLP-1s in 2026.	Bullish: GLP-1 revenue growth consistently at or above double-digits in 2026. Bearish: GLP-1 revenue growth falling below double-digits or significant deceleration.	Company earnings calls and press releases (Q3 2026 earnings call estimated for November 10, 2026).	Google Trends: 'GLP-1 drug sales', 'liraglutide prescription trends'. Publicly available pharmaceutical sales data (e.g., from WHO, CDC, FDA, KFF, J.P. Morgan, ASHP).	IQVIA: GLP-1 drug sales and prescription volumes. EvaluatePharma: Market share and growth rates for GLP-1 therapies.

Key Reported Metrics, Reratings Triggers & Results3 rows

GLP-1s represent a significant and growing market opportunity. Continued strong growth in this category is vital for Stevanato to capitalize on this high-demand

Upcoming print · 2026-11-05

Key reported metrics
Metric	Last period	Why it matters
GLP-1 Related Revenue Growth	Double-digit growth (guidance for full year)	GLP-1s represent a significant and growing market opportunity. Continued strong growth in this category is vital for Stevanato to capitalize on this high-demand therapeutic area and drive overall revenue.
Engineering Segment Revenue Growth	-2%	This segment has been a drag on overall performance. Improvement in order intake, backlog, and revenue trend is crucial for the company's overall growth and profitability, signaling a successful turnaround.
High-Value Solutions (HVS) Revenue Growth	EUR 135.9 million (16% y/y growth), 45% of total revenue	HVS is central to Stevanato's strategy, driving margin expansion and market leadership in biologics and GLP-1s. Sustained growth indicates successful execution and strong demand for premium offerings.

Last reported · 2026-08-04

Key reported metrics			Rerating thresholds			Earnings results
Metric	Last period	Why it matters	What's needed for rerating	Rerating context	Earnings date	Actual reported	Hit target?	Notes
Total Company Revenue	7%	Hitting this threshold validates STVN's strategy of leveraging high-value solutions and GLP-1 demand, offsetting Engineering segment challenges. It demonstrates strong execution, justifies a higher valuation, improves competitive positioning, and exceeds market expectations for sustained growth and profitability.	Stevanato Group S.p.A. (STVN) needs to report Q1 2026 total company revenue growth significantly above the 5% year-over-year reported in Q4 2025, ideally reaching low double-digits (e.g., 10%+ year-over-year). This should be coupled with strong 2026 revenue guidance that surpasses current growth rates and clearly exceeds peer averages, such as West Pharmaceutical Services' 5-7% organic growth forecast. Beating analyst consensus estimates for Q1 2026 would also be crucial.	Hitting this threshold validates STVN's strategy of leveraging high-value solutions and GLP-1 demand, offsetting Engineering segment challenges. It demonstrates strong execution, justifies a higher valuation, improves competitive positioning, and exceeds market expectations for sustained growth and profitability.	2026-08-04	EUR 302 million (8% y/y growth)	Partially	Total company revenue grew 8% year-over-year in Q2 2026, which is above the 5% reported in Q4 2025 but did not reach the ideal low double-digit (10%+) growth for rerating. The company updated its full-year 2026 revenue guidance to a range of EUR 1.260 billion to EUR 1.280 billion, reflecting a EUR 15 million reduction due to the Balda divestiture, partially offset by favorable currency translation and higher organic growth.
GLP-1 Revenue Growth	>20%	Exceeding the mid-teens GLP-1 revenue growth target would signal stronger-than-anticipated execution in a critical high-growth area. This would validate Stevanato's ability to capitalize on robust demand for biologics and GLP-1s, mitigating concerns about growth normalization and competitive dynamics, thereby justifying a higher valuation and improved competitive positioning.	Stevanato Group's GLP-1 Revenue Growth needs to exceed its reiterated 2026 guidance of mid-teens (e.g., 18-20% or higher). The company reported over 50% GLP-1 growth in 2025, which management described as an "initial surge". For 2026, they expect a normalization to mid-teens growth. A peer, West Pharmaceutical Services, expects GLP-1 and non-GLP-1 high-value product components to grow in the high teens organically for the full year 2026. Therefore, surpassing Stevanato's own mid-teens guidance would be a positive surprise against current market expectations.	Exceeding the mid-teens GLP-1 revenue growth target would signal stronger-than-anticipated execution in a critical high-growth area. This would validate Stevanato's ability to capitalize on robust demand for biologics and GLP-1s, mitigating concerns about growth normalization and competitive dynamics, thereby justifying a higher valuation and improved competitive positioning.	2026-08-04	Double-digit growth (guidance for full year)	No	While GLP-1s represented approximately 22% to 23% of total company revenue in Q2 2026, a specific year-over-year growth rate for the quarter was not provided. Management reiterated that they expect 'double-digit growth' for GLP-1s for the full year, which is less specific and potentially lower than the 'mid-teens (18-20% or higher)' rerating trigger.
High-Value Solutions Revenue	17%	Hitting these thresholds validates Stevanato's strategic shift towards premium integrated solutions, demonstrating sustained execution in high-growth biologics and self-administration markets. This signals continued margin expansion and strengthens its competitive position, driving a positive re-evaluation of its long-term valuation.	Stevanato Group's High-Value Solutions Revenue needs to consistently represent above 48% of total revenue, exceeding the high end of its 2026 guidance (47-48%). Concurrently, year-over-year growth of High-Value Solutions Revenue must re-accelerate significantly from Q1 2026's 17%, ideally reaching or exceeding 30% year-over-year, aligning with or surpassing peer performance.	Hitting these thresholds validates Stevanato's strategic shift towards premium integrated solutions, demonstrating sustained execution in high-growth biologics and self-administration markets. This signals continued margin expansion and strengthens its competitive position, driving a positive re-evaluation of its long-term valuation.	2026-08-04	EUR 135.9 million (16% y/y growth), 45% of total revenue	No	High-value solutions revenue grew 16% year-over-year, a slight deceleration from the prior quarter's 17% growth, and represented 45% of total company revenue in Q2 2026. This missed both components of the rerating trigger, which required HVS to be above 48% of total revenue and to re-accelerate to ideally 30% or more year-over-year growth. The full-year 2026 guidance for HVS is expected to range between 47% to 48% of total company revenue.

Key Questions

Will Stevanato Group achieve its double-digit GLP-1 revenue growth target for 2026 and maintain High-Value Solutions at 47-48% of total revenue, and how quickly

Will Stevanato Group achieve its double-digit GLP-1 revenue growth target for 2026 and maintain High-Value Solutions at 47-48% of total revenue, and how quickly will the newly approved Alina pen platform contribute to HVS growth and market share in the broader biologics space?

Question 2: Can the Engineering segment continue to improve its operational and financial performance in the second half of 2026, demonstrating a tangible increase in new order intake and backlog conversion to moderate its revenue decline faster than the mid-single to low double-digit expectation?
Question 3: How quickly will the Fishers facility achieve commercial production for its EZ-fill vial line and first device program in the second half of 2026, and how will the combined ramp-up of Fishers and Latina, along with the Balda divestiture, impact overall gross profit and adjusted EBITDA margins given ongoing depreciation and currency headwinds?

Earnings Transcript Summary4 rows

2026-08-04 · 2026Q2 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused On1. Optimizing portfolio towards high-value, integrated drug delivery systems: Management is focused on divesting non-strategic assets like Balda C. Brewer and investing in proprietary drug delivery platforms such as Alina and Deora, which combine device innovation with their cartridge technology to serve the biologics market. 2. Capitalizing on biologics and GLP-1 market opportunities: The company is strategically positioning itself to capture growth in injectable biologics, biosimilars, monoclonal antibodies, and GLP-1 therapies, which are seen as strong long-term tailwinds, by expanding capacity and developing integrated solutions. 3. Scaling growth investments and improving Engineering segment performance: Management is focused on ramping up operations at new facilities in Fishers (U.S.) and Latina (Italy) to meet customer demand for high-value solutions, while also executing an optimization plan for the Engineering segment to improve its operational and financial results.	Call Takeaway & ToneThe call conveyed a cautiously optimistic tone. Stevanato Group reported solid Q2 2026 results, largely in line with expectations, driven by strong growth in the Biopharmaceutical and Diagnostic Solutions (BDS) segment and high-value solutions, particularly in biologics and GLP-1 therapies. Management highlighted strategic moves like the Balda C. Brewer divestiture and the regulatory approval of the Alina pen as reinforcing their focus on higher-value, integrated solutions. While the Engineering segment showed continued operational and financial progress from optimization efforts, management remained cautious due to longer sales cycles. The company is confident in its long-term strategy centered on biologics and integrated drug delivery systems, supported by ongoing capacity expansions.	Prior Quarter'S Y/Y Growth By SegmentTotal Revenue: 7% (reported); Biopharmaceutical and Diagnostic Solutions (BDS) Segment: 13% (reported); Engineering Segment: -31%; High-Value Solutions: 17%; GLP1s (product category, within total revenue): >20%; Syringes (within BDS): >20%; Other Containment and Delivery Solutions (within BDS): 9%	3 Things Analysts Most Pressed On (And Mgmt Responses)1. Updated BDS growth outlook: Analysts questioned the change in BDS growth outlook to high single digits. Management clarified that the organic growth is still double-digit, with the reported change reflecting a EUR 15 million reduction from the Balda divestiture, partially offset by an EUR 8 million favorable currency impact and a slight increase in core organic growth. 2. GLP-1 vs. broader biologics growth and HVS drivers: Analysts inquired about the primary growth drivers for high-value solutions, specifically whether GLP-1s or other biologics were more significant. Management emphasized that while GLP-1s are a phenomenal and growing drug class, the company is "laser-focused" on the broader biologics market, which represents a much larger long-term opportunity with over 9,000 injectable assets in the global pipeline, 60% of which are biologics. 3. Alina product opportunity and premium HVS: Analysts asked about the specific premium products within high-value solutions and the commercial opportunity following the Alina pen platform's regulatory approval. Management expressed significant excitement about Alina, highlighting it as a proprietary, integrated system (pen + cartridges) that took 8 years to develop. They confirmed Alina revenue is included in 2026 guidance and is expected to generate double-digit revenue growth from Alina in the coming years, with Alba syringes also noted as a premium product.	Revenue SegmentsTotal Revenue: 8% year-over-year; Biopharmaceutical and Diagnostic Solutions (BDS) segment: 9% increase (10% at constant currency); Engineering segment: 2% decline; High-value solutions: 16% growth (45% of total company revenue); Revenue from biologics (within HVS): 30% increase; GLPs: approximately 22% to 23% of total company revenue; Other containment and delivery solutions (within BDS): 3% increase

2026-05-07 · 2026Q1 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused On1. Scaling and executing growth investments: Management is focused on leveraging strategic growth investments in facilities like Latina and Fishers to expand capacity for high-value solutions (e.g., syringes, cartridges) and ensure successful customer validations and commercial production ramp-up. 2. Optimizing the Engineering Segment: Management is dedicated to improving the Engineering segment's performance through optimization efforts, rightsizing operations, streamlining processes, and strengthening sales and marketing to drive growth and return to historical performance levels. 3. Capitalizing on the GLP-1 and broader biologics market: A significant focus is on maintaining and expanding their leadership in the GLP-1 market and increasing participation in other injectable biologics with their premium high-value product portfolio, including cartridges for large volume biologics.	Call Takeaway & ToneThe overall takeaway from the call is one of cautious optimism. Stevanato Group delivered solid Q1 2026 financial results, driven by strong performance in the Biopharmaceutical and Diagnostic Solutions (BDS) segment, particularly from high-value solutions and GLP-1s, supported by capacity ramp-up in Latina and Fishers. While the Engineering segment showed initial margin improvement due to optimization efforts, it remains a concern due to slow order intake and a low backlog. Management expressed confidence in the long-term growth trajectory of biologics and GLP-1s but acknowledged ongoing challenges in the Engineering segment and anticipated currency headwinds.	Prior Quarter'S Y/Y Growth By SegmentTotal Revenue: 5% (reported); Biopharmaceutical and Diagnostic Solutions (BDS) Segment: 10% (reported); Engineering Segment: -23%; High-Value Solutions: 31%; Other Containment and Delivery Solutions (within BDS): -9%	3 Things Analysts Most Pressed On (And Mgmt Responses)1. GLP-1 volume visibility and durability, and risk from orals: Analysts questioned the long-term outlook for GLP-1s and the potential impact of oral therapies. Management responded that they are positive on the GLP-1 outlook, reiterating mid-teens growth for 2026, largely covered by contractual commitments. They expect the market to continue to grow, with 70% still in injectables, and orals leading to market expansion rather than cannibalization. 2. Engineering segment recovery, order intake, and initiatives: Analysts pressed on the slower-than-anticipated order materialization in the Engineering segment. Management stated they are making progress on operational improvements and winning new contracts, expecting a stronger second half. They are focused on improving operational efficiency and increasing order intake, noting that sales cycles have lengthened due to slower customer decisions and more disciplined procurement. 3. BDS segment margins and factors impacting them: Analysts inquired about the moving parts in Q1 BDS margins and the outlook for the year. Management reiterated guidance for BDS gross profit margin to be in line or slightly better than last year, citing a better mix, but also headwinds from higher depreciation (especially in Q1), foreign currency (EUR 8 million impact on top line), and temporary tariffs (EUR 1.7 million impact).	Revenue SegmentsTotal Revenue: 7% (reported); Biopharmaceutical and Diagnostic Solutions (BDS) Segment: 13% (reported); Engineering Segment: -31%; High-Value Solutions: 17%; GLP1s (product category, within total revenue): >20%; Syringes (within BDS): >20%; Other Containment and Delivery Solutions (within BDS): 9%

2026-03-04 · 2025Q4 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused On1. Scaling High-Value Solutions Capacity and Execution: Management is focused on leveraging strategic growth investments in facilities like Latina and Fishers to expand capacity for high-value solutions (e.g., Nexa syringes, EZ-fill cartridges) and ensure successful customer validations and commercial production ramp-up. They emphasized running at "approximately full capacity" for prefilled syringes in 2025 and the continued positive momentum into 2026. 2. Optimizing and Repositioning the Engineering Segment: Management is dedicated to improving the Engineering segment's performance through optimization efforts, rightsizing operations, streamlining processes, and strengthening sales and marketing. While acknowledging slower order intake and a longer recovery than expected, they are focused on securing new, more standardized orders and leveraging operational improvements. 3. Capitalizing on the GLP-1 and Broader Biologics Market: A significant focus is on maintaining and expanding their leadership in the GLP-1 market, which was a major tailwind in 2025 and is expected to continue growing. Beyond GLP-1s, they are focused on increasing participation in other injectable biologics with their premium high-value product portfolio, aiming to be a key partner for all injection-based therapies.	Call Takeaway & ToneThe overall takeaway from the call is one of cautious optimism. Stevanato Group delivered solid financial results for Q4 and full-year 2025, driven by robust double-digit growth in its Biopharmaceutical and Diagnostic Solutions (BDS) segment and strong performance in high-value solutions, particularly from GLP-1s. Management expressed confidence in their strategic execution, capacity expansions in Latina and Fishers, and their positioning in the growing biologics and self-administration markets. However, the tone was notably cautious regarding the Engineering segment, acknowledging that its recovery and order intake are taking longer than expected, despite operational improvements. Currency headwinds are also anticipated for 2026. The company provided 2026 guidance reflecting continued high-value growth but a more muted outlook for Engineering, with an expectation of modest margin expansion and breakeven to positive free cash flow.	Prior Quarter'S Y/Y Growth By SegmentFor the third quarter of 2025: * Total revenue increased by 9% year-over-year. * Biopharmaceutical and Diagnostic Solutions (BDS) segment grew by 14% year-over-year. * Engineering segment declined by 19% year-over-year. * Revenue from high-value solutions grew 47%. * Revenue from other containment delivery solutions decreased by 10%.	3 Things Analysts Most Pressed On (And Mgmt Responses)1. GLP-1 Growth Outlook for 2026: Analysts questioned why the 2026 GLP-1 growth guidance (mid-teens) seemed conservative after 50% growth in 2025. Management responded that 2025 saw a "massive preparation of the supply chain" and an "initial surge," and a mid-teens growth in 2026 is a "realistic number" as products go commercial, followed by a "period of normalization where growth slows a bit." They also noted that beyond 2026, the market configuration (originator vs. biosimilar, pen vs. auto-injector) is still evolving. 2. Engineering Segment Recovery and Order Intake: Analysts pressed on the disappointing 2026 guidance for the Engineering segment and the reasons behind the low order intake. Management explained that while operational progress is strong (e.g., doubled site acceptance rates), the sales cycle for these technical lines is longer than anticipated, leading to delayed order confirmations. They reiterated that the underlying pharmaceutical market demand for new machines, especially for biologics and self-administration, is "robust" and the "pipeline is healthy," with a strong medium-term outlook. 3. High-Value Solutions Capacity vs. Demand and Margin Expansion: Analysts inquired about the utilization and capacity constraints for high-value solutions, particularly with the ramp-up of Fishers and Latina, and the drivers of margin expansion for 2026. Management confirmed that they ran "approximately full capacity" in 2025 for prefilled syringes and expect robust demand to continue playing a role in 2026. For margins, they guided for 0-30 basis points expansion, citing headwinds from higher depreciation and currency, but tailwinds from improving financial performance at Latina and Fishers as they scale, and a better project mix in Engineering.	Revenue SegmentsFor the fourth quarter of 2025: * Total company revenue increased by 7% at constant currency and 5% on a reported basis. * Biopharmaceutical and Diagnostic Solutions (BDS) segment revenue increased by 13% at constant currency and 10% on a reported basis. * Engineering segment revenue decreased by 23%. * Revenue from high-value solutions grew 31%, representing approximately 49% of total company revenue. * Revenue from other containment and delivery solutions (within BDS) decreased by 9%.

2025-11-07 · 2025Q3 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused On1. Executing Strategic Roadmap and Capacity Expansion: Management is focused on leveraging and scaling up growth investments in capacity expansion to meet increased demand for high-value products, particularly Nexa syringes and EZ-fill vials and cartridges, across their Fishers and Latina facilities. 2. Optimizing the Engineering Segment: Management is actively working on a business optimization plan for the Engineering segment, strengthening the sales organization, refining commercial processes, and repositioning the segment for stronger profitability, acknowledging that it will take more time to return to historical performance levels. 3. Meeting Demand for Injectable Biologics and Self-Administration: The company is focused on meeting the demands of high-growth markets like injectable biologics, which require premium containment and delivery solutions, and supporting the increasing trend towards self-administration of medicine with products like EZ-fill cartridges.	Call Takeaway & ToneThe overall takeaway from the call is one of cautious optimism. The company delivered solid third-quarter financial results, exceeding expectations primarily driven by strong performance in the BDS segment and record growth in high-value solutions. Management reiterated its full-year 2025 guidance despite foreign currency headwinds and challenges in the Engineering segment, demonstrating confidence in their strategic roadmap and the ability of high-value solutions growth to offset these impacts. The tone was positive regarding the BDS segment, high-value solutions, and the long-term market tailwinds from biologics and self-administration. However, there was a cautious tone regarding the Engineering segment, acknowledging that its recovery will take more time than initially expected, despite ongoing optimization efforts.	Prior Quarter'S Y/Y Growth By SegmentFor Q2 2025, the Biopharmaceutical and Diagnostic Solutions (BDS) segment grew by 10% year-over-year. The Engineering segment declined by 2% year-over-year in Q2 2025.	3 Things Analysts Most Pressed On (And Mgmt Responses)1. Q3 Outperformance and High-Value Solutions Growth: Analysts inquired about the $10 million outperformance in Q3 and the drivers of strong high-value solutions growth. Management responded that the $10 million was an acceleration of Q4 sales to accommodate customer supply chain needs, primarily in high-value solutions like high-performance syringes. They attributed high-value growth to strong demand for Nexa syringes, traction in Alba syringes, and a recovery in sterile vials. 2. Engineering Segment Recovery and Timeline: Analysts pressed on the timeline for the Engineering segment's return to growth and whether it could grow in 2026. Management acknowledged that while operational progress is being made, converting the healthy pipeline into new orders has been slower than anticipated, mainly due to key customers awaiting final acceptance tests and reevaluating manufacturing footprints. They believe the long-term demand landscape remains strong due to industry expansion and technology upgrades. 3. Biosimilar Opportunity, especially GLP-1s: Analysts asked about the broader picture of biosimilars, specifically GLP-1s, and their contribution to Stevanato's growth. Management explained that biosimilars help enlarge revenue for the industry, and Stevanato is deeply involved with both originator and biosimilar programs across its high-value product platform, including Nexa syringes and ready-to-fill cartridges. They view this as a net positive effect, translating into more orders for their products.	Revenue SegmentsTotal revenue increased by 9% year-over-year. The Biopharmaceutical and Diagnostic Solutions (BDS) segment grew by 14% year-over-year. The Engineering segment declined by 19% year-over-year. Revenue from high-value solutions grew 47%. Revenue from other containment delivery solutions decreased by 10%.

Transcript Tidbits5 rows

2026-08-04

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)
About Expanding Eligible MarketStevanato Group is seeing strong demand for injectable biologics, with over 9,000 injectable assets in the global drug pipeline, more than 60% of which are biologics. The rapid growth of biologics, GLP-1 therapies, and increasing patient adoption of self-administration are reshaping pharmaceutical product development. The company received regulatory approval in several European countries for its proprietary Alina variable dose pen platform for a liraglutide-based therapy, including variants for both diabetes and weight management. This approval is expected to boost traction for other validations worldwide, with additional validation anticipated in North America in the second half of the year. Stevanato also introduced Deora, a novel multi-use fixed-dose pen injector system compatible with prefilled cartridges up to 3 ml, to meet the need for treatments requiring strict patient adherence to dosing regimens. GLP-1s currently represent approximately 22% to 23% of total company revenue and are expected to be a strong long-term durable tailwind. Biologics, which represent about 42% of the BDS segment revenue, are seen as a much larger opportunity, spread across many clients and therapeutic areas, compared to the more concentrated GLP-1 market. Alina products are expected to generate double-digit revenue growth in the coming years.	About CompetitionStevanato Group is optimizing its footprint and accelerating its transition towards more complex, differentiated, and integrated drug delivery systems, as evidenced by the divestiture of its California-based subsidiary, Balda C. Brewer, which specialized in contract manufacturing of standard consumable products. The company aims to be a leader in biologic applications, focusing on higher-value subsets of the market. Stevanato emphasizes its 'integrated system approach,' selling its proprietary drug delivery systems (like Alina) with its glass cartridges inside, rather than just operating on a CMO business model. This positions them in what they call the 'Champions League' of the industry. They are actively serving both originator and biosimilar clients in the GLP-1 market with Nexa syringes, ready-to-fill cartridges, and their integrated Alina device. The company leverages its tech centers and specialized hubs to capture larger pieces of the supply chain and enhance its value proposition, supporting international biosimilar companies with devices, cartridges, filling, and regulatory support.	About The Broader IndustryDrug delivery systems are becoming increasingly strategic for the success of injectable therapies, leading to strong customer demand for integrated solutions that combine device innovation, manufacturing expertise, and supply chain reliability. Pharmaceutical companies are increasingly looking to outsource as much of their supply chain as possible. Customer needs are evolving, focusing on solutions that enhance patient usability and adherence, derisk the supply chain, better address new drug product requirements for modern formulations, and improve the sustainability and cost efficiency of combination products. The industry is characterized by longer sales cycles compared to previous years, and a generally prudent and conservative approach to new product adoption. The company noted higher utility costs and currency headwinds impacting gross profit margins. Additionally, the effective tax rate in Q2 2026 was higher due to the absence of a tax incentive available in Italy in fiscal year 2025 and no corresponding tax benefit on the sale of Balda C. Brewer.	Where Things Are HeadedStevanato Group expects to launch customer validation for the first EZ-fill vial line at its Fishers facility in the near term, with commercial production for its first device program there expected to begin later this year. The syringe ramp-up in Latina is ongoing, and the next-generation RTU 400 cartridge line is expected to be installed in the next couple of months, with commercial production anticipated in 2027. The company is positioning its business around biologics, GLP-1 therapies, and integrated drug delivery systems. For fiscal year 2026, the updated revenue guidance is EUR 1.260 billion to EUR 1.280 billion, adjusted EBITDA is expected between EUR 335 million to EUR 345.2 million, and adjusted diluted EPS is projected to be EUR 0.60 to EUR 0.62. The BDS segment is expected to grow high single digits on a reported basis, while the Engineering segment is projected to decline by mid-single digits to low double digits. High-value solutions are expected to represent 47% to 48% of total revenue, and free cash flow is anticipated to be between breakeven and positive EUR 20 million. The tax rate for 2026 is expected to be approximately 28.2% adjusted for the divestment. The company anticipates further margin expansion in the BDS segment in Q3 and Q4, driven by growth in Fishers and Latina and a stronger second half of the year. The Engineering segment is showing improving trends quarter-over-quarter, with a goal to return to original revenue and marginality numbers in 2027. Fishers is planned to be fully ramped up by the end of 2028.	Updates On ThemeLife	Broader Themes EmergingThe pharmaceutical industry is increasingly trending towards outsourcing large portions of the supply chain. There is a growing patient adoption of self-administration of medicines, driving demand for user-friendly and adherence-enhancing drug delivery systems. There is also an increasing focus on the sustainability and cost efficiency profile of combination products.	Bullish-Leaning Quotes (Short)Our second quarter financial results were largely in line with our expectations, highlighted by solid revenue growth and a better mix of high-value solutions that drove expanded margins and adjusted EBITDA of 26%. Demand for injectable biologics remains strong with more than 9,000 injectable assets in the global drug pipeline undergoing clinical evaluation or registration and more than 60% of those are biologics. We believe our broad portfolio of drug delivery platforms and our end-to-end capabilities positions Stevanato Group well to support this evolution. The approval represents an important commercial milestone for our proprietary drug delivery systems and includes 2 Alina variants for both diabetes and weight management applications. Alina, it will help to generate double-digit revenue around Alina products in next year to come. We expect in Q3 and Q4 further margin expansion in our BDS segment driven by the growth in Fishers and Latina and driven by the fact that we expect a stronger second half of the year.	Bearish-Leaning Quotes (Short)Offset a slight decline in Engineering segment. Sales cycles are longer today than in previous year. The subsidiary was expected to generate revenue of approximately EUR 30 million in fiscal year 2026 and the transaction is expected to be accretive on the full year margins. As expected, the tax rate in the second quarter of 2026 was higher compared with the same period last year. Gross profit margin decreased by 10 basis points to 31.1%. The operating profit margin was impacted by the sale of Balda and declined 330 basis points to 15.8%. Revenue from the Engineering segment decreased 2% to EUR 35.8 million. We continue to remain somewhat cautious due to the elongated sales cycle and project phasing.

2026-05-07

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
About Expanding Eligible MarketGLP1s accounted for approximately 21% to 22% of total company revenue in Q1 2026, driving a 15% increase in revenue from biologics. The market for GLPs and incretin therapies is expected to continue to grow and evolve over the next decade with novel indications beyond diabetes and obesity, new originators in clinical phases, and biosimilars gaining traction. Demand for cartridges is extending into many other traditional large pharma and emerging biotech players for biologics, including large volumes up to 20 ml for home-based subcutaneous injections. The company converted an underutilized ready-to-use vial line to a ready-to-use cartridge line in Piombino Dese and is preparing for the next phase of expansion for EZ-fill cartridges in Latina with new RTU 400 lines. Annex 1 regulations are seen as a longer-term accelerator for ready-to-use adoption. The market opportunity for GLP-1s is vast, with over 150 million potential patients in the U.S. and 1.5 billion globally. A new service offering for large batch, Not for Human Use fill and finish services has been launched.	About CompetitionThe company anticipates continued benefits as more originators and biosimilars enter the GLP-1 market. Stevanato Group aims to be #1 or #2 in its core product categories within the injectables market and is progressively de-emphasizing non-core products in favor of more accretive solutions. The sales cycle has lengthened, and decision cycles are slower across the industry, with more disciplined procurement and higher hurdles with CapEx committees, a trend observed among peers.	About The Broader IndustryThe industry is seeing a shift towards home-based subcutaneous injections for biologics, driven by higher drug potency. Annex 1 regulations are driving higher standards for contamination control and quality risk management, accelerating ready-to-use adoption. The injectable biologics market is expected to see strong growth, fueled by biosimilars, monoclonal antibodies, and other advanced therapies. Inflationary pressures, including gas prices, energy, logistics, and supplier costs, are impacting the industry, with companies working to mitigate these effects through price adjustments with customers.	Where Things Are HeadedCommercial production at the Fishers facility is expected to begin at the end of 2026 or early 2027. Commercial production of RTU cartridges on the new Latina line is set to launch in early 2027. The company is maintaining its 2026 guidance for revenue (EUR 1.260 billion to EUR 1.290 billion), adjusted EBITDA (EUR 331.8 million to EUR 346.9 million), and adjusted diluted EPS (EUR 0.59 to EUR 0.63). The second half of 2026 is expected to be stronger than the first half. The GLP-1 market is projected to continue growing for several years with predictable volumes for 2026. The Engineering segment anticipates a stronger second half of the year, with an expected decline of mid-single digits to low double digits compared to 2025. BDS gross profit margin for the year is expected to be in line with or slightly better than last year, and high-value solutions are projected to represent 47% to 48% of total revenue for the year.	Updates On ThemeLife	Broader Themes EmergingOnshoring manufacturing (U.S. as a strategic hub for domestic supply).	Bullish-Leaning Quotes (Short)We started fiscal 2026 with strong momentum in the first quarter, highlighted by 10% revenue growth on a constant currency basis. The market for GLPs and incretin therapies is expected to continue to grow and evolve over the next decade. We are confident that we will continue benefiting in the future as more originators and biosimilars enter the market. We believe that we are well positioned to support our customers and to continue capitalizing on the rising growth in biologics and injectable therapies.	Bearish-Leaning Quotes (Short)customer orders are materializing slower than expected. we still have work to do to secure new orders and rebuild the backlog to drive sustainable improvements in the segment's financial performance. we remain somewhat cautious due to the low backlog and the time required to get new orders over the finish line. The sales cycle overall has lengthened. And perhaps it's really the decision cycle. As expected, the biggest factor was higher depreciation related to the ramp-up in Fishers and Latina. the headwind from foreign currency. the impact of tariffs, some of which are expected to be recover in future periods.	HiringThe company is strengthening its commercial organization with new talent in the U.S. and Europe for the Engineering segment. The U.S. team is expanding as the Fishers facility builds its presence as a strategic hub for domestic supply.

2026-03-04

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)
About Expanding Eligible MarketKey signals point to expanding eligible market: strong growth in high-value solutions driven by Nexa syringes and EZ-fill vials (approximately 46-47% growth) and a shift to ready-to-use platforms that support self-administration; GLP-1 biosimilar activity and broader biologics demand supported by ready-to-use cartridges and autoinjector formats; accelerating capacity build in the U.S. (onshoring) with major pharma players investing in U.S. manufacturing to meet higher quality standards and stricter regulations (e.g., Annex 1); ongoing capital investments at Fishers and Latina to scale Nexa, EZ-fill and related lines, with continued growth expected through 2026 and beyond to meet rising biologics demand.	About CompetitionCompetition dynamics center on biosimilars' growing role and the need for integrated, high-value packaging and delivery solutions. Biosimilars can broaden revenue across originator and biosimilar programs (roughly 70% originator, 30% biosimilar when patents expire), and management emphasized maintaining leadership across Nexa, Alba and EZ-fill platforms. The company noted currency headwinds and tariff costs, implying pricing and regulatory pressures that could affect margins. The ambition to become a fully integrated high-value solutions provider suggests differentiation but also intensifies competition with peers expanding into end-to-end systems (e.g., larger players in packaging and devices).	About The Broader IndustryIndustry trends include robust growth in injectable biologics, a shift toward ready-to-use platforms, self-administration, and regulatory tightening (Annex 1). Onshoring of manufacturing toward the United States is accelerating as customers reassess footprints. Major capacity investments at Fishers and Latina to support biologics and auto-injector ecosystems, plus new lines and clean rooms for Alina Pen and broader CMO initiatives, indicate a multi-year capacity build and increased focus on high-value biologics packaging and devices; sustainability ESG milestones are also part of industry evolution.	Where Things Are HeadedOutlook remains constructive: 2026 guidance centers High-Value Solutions at 47-48% of revenue; currency headwinds expected but offset by organic growth; continued capacity ramp at Fisher and Latina to sustain longer-term growth toward 2028; investments in EZ-fill, Nexa, Alba, and ready-to-fill cartridges, plus the new Germany clean room for Alina Pen; potential upside from broader CMO initiatives and expanded biologics applications.	Updates On ThemeGLP1	Broader Themes EmergingBiologics growth, ready-to-use platforms, self-administration, onshoring manufacturing, and end-to-end integration in packaging and devices; regulatory tightening and tariff headwinds; biosimilars expansion; capacity expansion across US and Europe.	Bullish-Leaning Quotes (Short)We remain on track to meet our 2025 guidance. The industry expands its capacity to satisfy growing demand for injectable biologics and devices. EZ-fill cartridges are setting a new standard. We are well-positioned to meet evolving industry demands and support patient-centric solutions.	Bearish-Leaning Quotes (Short)Foreign currency translation was a headwind. Certain tariff costs were not mitigated. The current slowdown in order flow is not permanent and will take time to recover.

2025-11-07

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
About Expanding Eligible MarketKey signals point to expanding eligible market: (1) strong growth in high-value solutions driven by Nexa syringes and EZ-fill vials (46-47% growth noted) and a shift to ready-to-use platforms that support self-administration; (2) GLP-1 biosimilar activity and broader biologics demand supported by a focus on ready-to-use cartridges and autoinjector-compatible formats; (3) accelerating capacity build in the U.S. (onshoring) with major pharma players investing in U.S. manufacturing to meet higher quality standards and stricter regulations (e.g., Annex 1); (4) ongoing capital investments at Fisher and Latina to scale Nexa, EZ-fill and related lines, with expectations of continued growth through 2026 and beyond to meet rising biologics demand.	About CompetitionCompetition dynamics center on the growing role of biosimilars and the need for integrated high-value packaging and delivery solutions. Management stressed that biosimilars can broaden revenue opportunities across originator and biosimilar products (roughly 70% originator, 30% biosimilar when patents expire) and highlighted the importance of maintaining leadership across Nexa, Alba and EZ-fill platforms. They also noted a cautious outlook due to currency headwinds and tariff costs, implying pricing and regulatory pressures that could affect margins. The goal to become a fully integrated high-value solutions provider implies competitive differentiation but also intensifies competition with peers expanding into end-to-end systems.	About The Broader IndustryIndustry trends include strong growth in injectable biologics, a broad shift to ready-to-use platforms, self-administration, and regulatory tightening (Annex 1). The transcript reinforces onshoring as customers reevaluate manufacturing footprints toward the United States, with substantial investments in new capacity and clean rooms to support biologics and auto-injector ecosystems. Firms are prioritizing high-value, integrated solutions and expanding manufacturing networks to meet demand while pursuing sustainability (ESG milestones).	Where Things Are HeadedProspects remain positive with guidance reaffirmed for 2025. High-value solutions are expected to represent 43–44% of revenue (up from prior 40–42%), currency headwinds anticipated but offset by organic growth, and ongoing capacity ramp at Fisher and Latina to support longer-term growth toward 2028 (aiming for full capacity and roughly $0.5B in revenue uplift). The company plans continued investment in EZ-fill, Nexa, Alba, and new lines for ready-to-fill cartridges, plus a new Germany clean room for Alina Pen and broader CMO initiatives, signaling a multi-year growth trajectory and potential upside into 2026 and beyond.	Updates On ThemeGLP1	Bullish-Leaning Quotes (Short)We remain on track to meet our 2025 guidance.; The industry expands its capacity to satisfy growing demand for injectable biologics and devices.; EZ-fill cartridges are setting a new standard.; We are well-positioned to meet evolving industry demands and support patient-centric solutions.	Bearish-Leaning Quotes (Short)Foreign currency translation was a headwind.; Certain tariff costs were not mitigated.; The current slowdown in order flow is not permanent and will take time to recover; Getting the segment back to historical performance levels is going to take more time.	HiringStrengthening the sales organization with fresh expertise and refining our commercial processes; reinforcing our commercial teams to support growth across high-value platforms and ready-to-use solutions.

2025-11-07

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
About Expanding Eligible MarketKey signals point to expanding eligible market: (1) strong growth in high-value solutions driven by Nexa syringes and EZ-fill vials (46-47% growth noted) and a shift to ready-to-use platforms that support self-administration; (2) GLP-1 biosimilar activity and broader biologics demand supported by a focus on ready-to-use cartridges and autoinjector-compatible formats; (3) accelerating capacity build in the U.S. (onshoring) with major pharma players investing in U.S. manufacturing to meet higher quality standards and stricter regulations (e.g., Annex 1); (4) ongoing capital investments at Fisher and Latina to scale Nexa, EZ-fill and related lines, with expectations of continued growth through 2026 and beyond to meet rising biologics demand.	About CompetitionCompetition dynamics center on the growing role of biosimilars and the need for integrated high-value packaging and delivery solutions. Management stressed that biosimilars can broaden revenue opportunities across originator and biosimilar products (roughly 70% originator, 30% biosimilar when patents expire) and highlighted the importance of maintaining leadership across Nexa, Alba and EZ-fill platforms. They also noted a cautious outlook due to currency headwinds and tariff costs, implying pricing and regulatory pressures that could affect margins. The goal to become a fully integrated high-value solutions provider implies competitive differentiation but also intensifies competition with peers expanding into end-to-end systems.	About The Broader IndustryIndustry trends include strong growth in injectable biologics, a broad shift to ready-to-use platforms, self-administration, and regulatory tightening (Annex 1). The transcript reinforces onshoring as customers reevaluate manufacturing footprints toward the United States, with substantial investments in new capacity and clean rooms to support biologics and auto-injector ecosystems. Firms are prioritizing high-value, integrated solutions and expanding manufacturing networks to meet demand while pursuing sustainability (ESG milestones).	Where Things Are HeadedProspects remain positive with guidance reaffirmed for 2025. High-value solutions are expected to represent 43–44% of revenue (up from prior 40–42%), currency headwinds anticipated but offset by organic growth, and ongoing capacity ramp at Fisher and Latina to support longer-term growth toward 2028 (aiming for full capacity and roughly $0.5B in revenue uplift). The company plans continued investment in EZ-fill, Nexa, Alba, and new lines for ready-to-fill cartridges, plus a new Germany clean room for Alina Pen and broader CMO initiatives, signaling a multi-year growth trajectory and potential upside into 2026 and beyond.	Updates On ThemeGLP1	Bullish-Leaning Quotes (Short)We remain on track to meet our 2025 guidance.; The industry expands its capacity to satisfy growing demand for injectable biologics and devices.; EZ-fill cartridges are setting a new standard.; We are well-positioned to meet evolving industry demands and support patient-centric solutions.	Bearish-Leaning Quotes (Short)Foreign currency translation was a headwind.; Certain tariff costs were not mitigated.; The current slowdown in order flow is not permanent and will take time to recover; Getting the segment back to historical performance levels is going to take more time.	HiringStrengthening the sales organization with fresh expertise and refining our commercial processes; reinforcing our commercial teams to support growth across high-value platforms and ready-to-use solutions.

Notes2 rows

Date	Comment	Comment Type	Comment Sentiment	Link	Price Reaction
2026-03-04	Stevanato Group reported solid Q4 and FY25 results, driven by strong double-digit growth in high-value solutions, particularly Nexa syringes for GLP-1s. The company provided positive 2026 guidance, forecasting mid-teens GLP-1 growth and continued BDS segment strength, despite ongoing Engineering segment challenges. The stock's 4.62% rise, significantly outperforming the SPY, indicates the market perceived the results and outlook positively, aligning with the company's strategic focus on high-growth biologics.	Other	Bullish		+4.62% (vs SPY: +5.79%)
2026-08-04	Stevanato Group reported solid Q2 2026 results, driven by strong biologics and GLP-1 demand, and the Alina pen approval. The Balda divestiture and Engineering segment's decline were noted. Despite positive messaging and guidance adjustments, the stock underperformed the SPY by 2.90% in the two days post-earnings, suggesting market caution, possibly due to the Engineering segment's continued weakness or the slight revenue guidance reduction.	Earnings Transcript	Neutral		-1.46% (vs SPY: -2.90%)

Upcoming Events9 rows

Catalyst ID	Estimated Timing	Estimated Date Start	Estimated Date End	Catalyst	Why It Matters	Ticker Or Theme Specific	Transcript Date	Source Type
STVN_18398d39	early 2027	2027-01-01	2027-03-31	Launch of commercial production of RTU cartridges on the new RTU 400 EZ-fill cartridge lines at Latina.	This expansion will bring much-needed capacity for high-speed, high-output ready-to-use cartridges, addressing rising global demand and driving operational efficiency and revenue growth for Stevanato Group.	Ticker	2026-05-07	earnings_transcript
STVN_bc850de3	at the end of 2026 or early 2027	2026-10-01	2027-03-31	Commencement of commercial activities for contract manufacturing of large device programs at the Fishers facility.	This represents a new revenue stream and leverages the company's capabilities in drug delivery devices, contributing to overall growth and diversification.	Ticker	2025-11-07	earnings_transcript
STVN_90225f22	the GLP-1 in the next decade, it will continue to be a powerful tailwinds	2027-01-01	2036-12-31	The evolving landscape of the GLP-1 market, including the mix of injectables vs. orals, originator vs. biosimilar strategies, and new product launches.	This evolution will determine the long-term demand trajectory for Stevanato's high-value syringes, cartridges, and devices, impacting its sustained growth and market leadership in this critical therapeutic area.	Theme	2026-03-04	earnings_transcript
STVN_ced6ef02	commercial activities to begin at the end of 2026 or early 2027 for the first device program	2026-10-01	2027-03-31	Commencement of commercial activities for the first large device program at the Fishers facility for a key U.S. customer.	This represents a new significant revenue stream from contract manufacturing activities, leveraging integrated capabilities and high-value solutions for a major client.	Ticker	2026-03-04	earnings_transcript
STVN_ca09a557	at the end of 2028	2028-10-01	2028-12-31	Fishers facility reaching full production capacity and generating $0.5 billion in revenue.	Achieving full capacity at Fishers will significantly boost high-value solution revenue, improve overall company margins, and validate the strategic investment in the facility.	Ticker	2025-11-07	earnings_transcript
STVN_b86df9cd	line installations and customer validation activities are expected to continue all year	2026-09-17	2026-09-17	Continued progress and successful completion of line installations and customer validation activities at the Fishers facility throughout 2026.	This is essential for ramping up capacity for high-value syringes and other products in the US, meeting customer demand, and improving the facility's financial performance.	Ticker	2026-03-04	earnings_transcript
STVN_7fce4c2f	this year, we're going to install the first high-speed line forecast is way to fill, but the goal is to do the validation is yet to start to do commercial revenue in the beginning of 2027	2026-03-07	2027-03-31	Successful installation, validation, and commencement of commercial revenue generation from new high-speed EZ-fill cartridge lines at the Latina facility.	This expansion is critical to meet rising global demand for cartridges, support new pen injector formats and biosimilars, and drive future high-value solutions growth and margin expansion.	Ticker	2026-03-04	earnings_transcript
STVN_5a8f34f7	continue into 2026	2026-01-01	2026-12-31	Continued scaling of commercial production for Nexa Syringes at the Latina facility.	Increased production capacity for high-demand Nexa syringes will drive revenue growth in high-value solutions and improve operating leverage at the Latina plant.	Ticker	2025-11-07	earnings_transcript
STVN_d69cac2b	throughout 2026	2026-01-01	2026-12-31	Continued installation and customer validation of additional syringe lines at the Fishers facility.	This will increase capacity for high-value solutions, driving revenue growth and margin expansion as the facility scales and gains operating leverage.	Ticker	2025-11-07	earnings_transcript